Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2022-06-06
- Target Recruit Count
- 149
- Registration Number
- NCT04448756
- Locations
- 🇺🇸
LAC-USC Medical Center, Los Angeles, California, United States
🇺🇸Sharp Chula Vista Medical Center, San Diego, California, United States
🇺🇸Henry Ford Medical Center, Detroit, Michigan, United States
Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 146
- Registration Number
- NCT04246489
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Stanford University Hospital and Clinics - Stanford Cancer Center, Stanford, California, United States
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
- Conditions
- Metastatic or Locally Advanced Unresectable Solid Tumors
- Interventions
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 204
- Registration Number
- NCT04170153
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, Austin, Texas, United States
🇺🇸Mary Crowley Cancer Research Centers, Dallas, Texas, United States
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2023-03-24
- Target Recruit Count
- 10
- Registration Number
- NCT04075721
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Georgetown University Medical Center- Research Parent, Washington, District of Columbia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
- Conditions
- CholangiocarcinomaGallbladder CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 309
- Registration Number
- NCT04066491
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers - Chandler II, Chandler, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Study of Evobrutinib in Participants With RMS
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 1
- Registration Number
- NCT04032171
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact the Communication Center, Darmstadt, Germany
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2021-08-05
- Target Recruit Count
- 3
- Registration Number
- NCT04032158
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
🇩🇪Please Contact the Communication Center, Darmstadt, Germany
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
- Conditions
- Multiple Sclerosis (MS)
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-10-31
- Target Recruit Count
- 662
- Registration Number
- NCT03961204
- Locations
- 🇺🇸
MS Center of Atlanta, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore - Maryland Center for MS, Baltimore, Maryland, United States
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2025-02-20
- Target Recruit Count
- 140
- Registration Number
- NCT03940703
- Locations
- 🇺🇸
Yuma Regional Medical Center, Yuma, Arizona, United States
🇺🇸Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸Memorial Care, Long Beach, California, United States
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-04-29
- Target Recruit Count
- 100
- Registration Number
- NCT03933215
- Locations
- 🇺🇸
VCU Medical Center - Pediatric Neurology, Richmond, Virginia, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸HCA Research Institute, Englewood, Colorado, United States